Use of reverse transcription-PCR-based assays for quantification of HIV-1 in dried blood spots requires specific HIV-1 RNA isolation for monitoring of antiretroviral treatment efficiency.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

1. Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots.Journal of clinical microbiology · 2016
   Article
2. Estimation of HIV-1 DNA Level Interfering with Reliability of HIV-1 RNA Quantification Performed on Dried Blood Spots Collected from Successfully Treated Patients.Journal of clinical microbiology · 2016
   Article

Corrections and comments

• Comment on
  Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia.2014

Authors and funding

8 authors at 6 institutions in 4 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as